Israel-based company, InMode (INMD.US), specializing in minimum-invasive and non-invasive medical technologies announced significant changes in a leadership today: departure of Shakil Lakhani, President of North America, alongside with Chief Medical Officers, and Dan Wilson, VP of Sales USA.
- The company want to optimize its structure amid falling revenues and EPS; struggling to enter new, wellness sector. InMode is well-known for its radiofrequency (RF) technology-based devices, using in plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology.
- Current InMode valuation is weak, if we assume that the company still has very high net margin (more than 40% in Q2 2024) and just $9 million debt vs more than $750 million in cash and cash equivalents; market cap of $1.3 billion. Despite huge slowdown in sales and net earnings. The biggest risk for the company is now the war escalation risk (headquarter in Yokneam, Israel), with Iran bombing Israel.
Source: Bloomberg Finance L.P , XTB Research
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile app
Source: XTB Research
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
